Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration
← catalyst calendarNCT01736592 · readout in 2,567 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Other
Enrollment
27actual
Sites
2
Countries
France, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2012-12-14 | actual | When the study began enrolling |
| Primary completion | 2033-08-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-08-29 | estimated | The whole study's end, after follow-up |
| First posted | 2012-11-29 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Stargardt's Disease
Intervention
- Drug: Long term follow up in all patients who received SAR422459 in previous study TDU13583
Primary outcome
what the primary-completion date above is the date OFThe incidence of Adverse Events
measured 15 years
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed